Group items tagged

This Funding Opportunity Announcement (FOA) solicits Small Business Technology Transfer (STTR) grant applications from small business concerns (SBCs) to develop medium- to high-throughput assays to evaluate the effects of toxicants on pluripotent or induced pluripotent cells with respect to cell differentiation and the resulting differentiated cell populations. The ability to incorporate genetic diversity in these assays would be useful.  These assays will provide information on mechanisms of chemically-induced biological activity, help to prioritize chemicals for more extensive toxicological evaluation, support more predictive models of in vivo biological response, and potentially inform on the role of genetic diversity in toxicological effects.

There is a need to develop technologies that support research using zebrafish models of biomedical value. The zebrafish has become increasingly important as a biological resource, because of its small size, short generation time, easy manipulation of embryos and optical transparency. This animal model is used to study aspects of gene structure and function that can be directly related to human genetics and disease. Zebrafish are also important for studies in diverse disciplines, including pharmacology, toxicology, neurobiology, behavior and developmental biology. This funding opportunity announcement (FOA) encourages applications from small business concerns (SBCs) for Small Business Innovation Research (SBIR) projects that propose innovative research and development of technology, including reagents and high throughput equipment, to support different aspects of the creation, detection, identification and characterization of zebrafish models of human disease and preservation of genetic stocks.

This Funding Opportunity Announcement (FOA) encourages Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop and translate medical technologies aimed at reducing disparities in healthcare access and health outcomes. Appropriate medical technologies should be effective, affordable, culturally acceptable, and deliverable to those who need them. Responsive grant applications must involve a formal collaboration with a healthcare provider or other healthcare organization serving one or more health disparity populations during Phase I and Phase II.

The SBIR Road Tour will visit Ohio State University on June 20. The SBIR Road Tour is a national outreach effort to convey the non-dilutive technology funding opportunity provided through the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs. Federal and State Program Managers representing the $2.5 billion in early stage funding have been invited to attend a series of events alongside technology entrepreneurs and innovation supporters from across the United States.

The purpose of the administrative supplement is to provide support for NIH-funded investigators to participate in an entrepreneurship training course, the Concept to Clinic: Commercializing Innovation (C3i) Program. The C3i Program is designed to provide medical device innovators with the specialized business frameworks and essential tools for successful translation of biomedical technologies from the lab (concept) to the market (clinic). Through this program, the NIH fosters the development and commercialization of early-stage biomedical technologies by engaging investigators who are interested in better understanding the value of their innovation in addressing an unmet market need. The curriculum and customized mentoring provided by the C3i Program are intended to guide investigators as they assess the commercial viability and potential business opportunity for their innovation. Prospective applicants are strongly encouraged to contact NIH Scientific/Research staff for more information about the program before applying.

The purpose of the administrative supplement is to provide support for NIH-funded investigators to participate in an entrepreneurship training course, the Concept to Clinic: Commercializing Innovation (C3i) Program. The C3i Program is designed to provide medical device innovators with the specialized business frameworks and essential tools for successful translation of biomedical technologies from the lab (concept) to the market (clinic). Through this program, the NIH fosters the development and commercialization of early-stage biomedical technologies by engaging investigators who are interested in better understanding the value of their innovation in addressing an unmet market need. The curriculum and customized mentoring provided by the C3i Program are intended to guide investigators as they assess the commercial viability and potential business opportunity for their innovation. Prospective applicants are strongly encouraged to contact NIH Scientific/Research staff for more information about the program before applying.

The NIH Research Evaluation and Commercialization Hub (REACH) program is envisioned as a partnership program between NIH and the qualifying research institutions to accelerate the creation of small businesses and the transition of discoveries originating from academic research into products that improve health. REACH Hubs will foster the advancement of therapeutics, preventatives, diagnostics, devices, and tools in a manner consistent with business case development, that address the needs of patients and public health.

WHO CAN APPLY? I-Corps@Ohio funds will be offered on a competitive basis to teams of faculty researchers and graduate students developing institution-based technologies from Ohio colleges and universities. Under the supervision of business and entrepreneurial mentors, teams will develop market-driven value propositions and scalable business models around their technologies and attract follow on funding to support company formation and market entry. APPLICATION PROCESS The I-Corps@Ohio proposal submission process consists of five steps: 1. mandatory meeting with the appropriate TTO representative(s) at the PI's institution; 2. team selection of technology track (science and engineering or medtech); 3. registration of all team members in the online portal; 4. proposal submission; and 5. full team interview with I-Corps@Ohio program representatives. All teams are required to complete the online profile and submission questionnaire beginning October 23, 2019. Deadline to apply is January 15, 2019. The PI may complete this information or designate another member of the team as the lead member. Subsequent members of the team will be invited to join by the lead member through the application portal and must complete his or her profile. Every effort should be made to identify all team members prior to submitting the online proposal submission questionnaire. Additional team members may be added later. You will be asked to select from two tracks: Medtech Track: Teams will select Medtech Track if the subject technology is in the form of medical devices, diagnostics, medicines, vaccines, software, testing procedures and systems and is developed to solve a health/clinical problem and improve the quality of human life. Science and Engineering (S&E) Track: Teams will select S&E Track if the technology does not fit into the Medtech category.

I-Corps@Ohio is a statewide program developed to assist faculty, staff and students from Ohio universities, colleges and community colleges in validating the market potential of technologies and launching startup companies. I-Corps@Ohio is modeled after the National Science Foundation's (NSF) successful I-Corps (Innovation Corps) program, which has been proven to increase innovation, entrepreneurship, and industry collaboration. The I-Corps@Ohio program incorporates lean launch, customer discovery and business model innovation methodologies to assess technologies, enhance the business acumen of research faculty and students and expand their entrepreneurial network relationships. Two cohort tracks are offered in Science & Engineering and Medtech, with each designed to offer both common and subject matter specific content. The long-term objective of I-Corps@Ohio is to systematically build a steady and predictable pipeline of  high-quality, high-growth startups from technology developed at the State's colleges, universities, and research institutions, that contribute to economic development in Ohio.

Our goal is to connect businesses and organizations that are best-positioned to address critical needs during this public health crisis, often in innovative or unexpected ways. Then we support those businesses to do what they do best: scale products and services that can help the American public. In the immediate term, we are keenly focused on working with companies-large and small-to spur development of personal protective equipment for medical and non-medical use, novel testing solutions, widely-accessible therapeutics and health services to address the needs of underserved communities. As the crisis evolves, we will continue to be responsive by tackling other urgent priorities.

Join BioOhio and the Columbus chapter of the Healthcare Businesswomen's Association (HBA) for a FREE online event - our second Diversity in Bioscience & Healthcare event of 2020, on August 20 at 5 pm. The engaging discussion focuses on the importance of supporting STEM programming at an early age within under-represented communities to encourage careers within the science and healthcare industries. Our special guests include: Frederic Bertley, Ph.D., President & CEO, COSI Kirsten M. Ellenbogen, Ph.D., President & CEO, Great Lakes Science Center Kelly Lewis, Bioscience Technologies Program Instructor, Eastland-Fairfield Career and Technical Schools Lead by the talented Brooke Cartus, Director of Business Development and Senior Facilitator, ImprovEdge! Featuring networking opportunities during the event! This discussion will be held via Zoom. Login instructions are included in your registration confirmation email and reminder emails sent before the event. BioOhio and the Healthcare Business Women's Association (HBA) support all efforts to increase diversity and inclusion within the bioscience and healthcare industries and invite you to join us for our next discussion, Overcoming Obstacles in the Workplace: Making Work Accessible on November 14th, 2020. This event is brought to you by BioOhio in partnership with the Columbus chapter of the Healthcare Businesswomen's Association (HBA) and is made possible by the generous support of BioOhio members AtriCure and BIO.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage small businesses to address the technological needs of the Kidney Precision Medicine Project (KPMP). The KPMP will obtain and evaluate kidney biopsies from participants with acute kidney injury (AKI) and chronic kidney disease (CKD), create a kidney tissue atlas, define disease subgroups, and identify critical cells, pathways and targets for novel therapies. Proposed technologies are expected to improve the safety of the human kidney biopsy or enhance interrogation of human kidney tissue, thus ensuring that the kidney biopsy yields useful research or clinical information.

The purpose of this Funding Opportunity Announcement (FOA) is to encourage small businesses to address the technological needs of the Kidney Precision Medicine Project (KPMP). The KPMP will obtain and evaluate kidney biopsies from participants with acute kidney injury (AKI) and chronic kidney disease (CKD), create a kidney tissue atlas, define disease subgroups, and identify critical cells, pathways and targets for novel therapies. Proposed technologies are expected to improve the safety of the human kidney biopsy or enhance interrogation of human kidney tissue, thus ensuring that the kidney biopsy yields useful research or clinical information.

This Small Business Technology Transfer (STTR) Funding Opportunity Announcement (FOA) seeks to stimulate research on and development of (R&D) wearable, mobile-based, or other technology (software applications, etc.) to collect continuous data on variables assessing functions of daily activities in individuals at risk for or with Alzheimer's disease (AD) or AD-related dementias (ADRD).

The Biomedical Advanced Research and Development Authority (BARDA), Division of Research, Innovation and Ventures (DRIVe) is releasing this ÂœDRIVe Accelerator Network Funding Opportunity Announcement (FOA) to solicit applicants interested in working with BARDA DRIVe to stimulate the public good by creating or leveraging a network of accelerators across America to promote national health security innovation. In order to address the serious 21st century health threats facing our nation, BARDA DRIVe invests in innovative products (therapies, vaccines, diagnostics, and devices), technologies and tools in order to increase our capability and capacity to respond. Collectively, these will be referred to as health security products and technologies. Applicants who enter agreements with BARDA will become members of the Accelerator Network to: Support BARDA DRIVe health security products and technologies as they navigate research, development, and regulatory pathways; Provide wrap-around services to assist the R&D efforts (such as technical and business advice, access to facilities and incubator spaces, integration services);

This Funding Opportunity Announcement (FOA) invites Small Business Innovation Research (SBIR) grant applications for funding to perform research leading to the development of novel and supportive technologies for the improvement of cell replacement interventions using novel methods, biomaterials and devices for type 1 diabetes (T1D) treatment.

This Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) Fast Track grant applications that propose to test and/or validate novel, state-of-the-art candidate biomarker platforms for predicting the onset and progression of inflammatory diseases of interest to the NIAMS and for determining the pharmacodynamics, safety and/or efficacy of therapeutic agents targeting those diseases. 

The purpose of this initiative is to incentivize small businesses to generate new technologies and products for delivering nucleic acids into cells and tissues for the purpose of treatment or prevention of human disease. 

Each Richard and Mary Finkelstein Student Travel Grant Award is $500 for use in attending asm2014 to present a poster in addition to being invited to give a short presentation of the abstract during the Division B and D Business Meeting.

The PCC has supported world-class research since 2009, spending more than $8.0 M to support novel science. Research and grant-making are the foundation of the PCC and are the focus of everyday business activity. PCC-supported research contributes to a movement in addressing doping's root causes and ultimately decreasing the use of performance-enhancing drugs by all participants in all sports at all levels of play. With an emphasis on original work that focuses on improving existing analytical methods for detecting particular drugs, developing new analytical methods to test for substances not currently detectable, and discovering cost-effective approaches for testing widely abused substances across all levels of sport, the following areas of investigation reflect the PCC's current research priorities: - Developing methods of cost-effective testing to detect and deter the use of banned and illegal substances. - Developing testing protocols to detect designer substances used for doping purposes. - Improving existing analytical methods to detect particular drugs, ex. GH, IGF-1, EPO, hCG. - Developing analytical methods to detect performance enhancing drugs not currently detectable. - Longitudinal urinary excretion patterns, metabolism and dose-concentration. - Critical reviews to support interpretation of laboratory data. - Alternative specimens, (ex. oral fluid, dried blood/plasma spots) for testing.

Stem cell technology holds the promise of providing a nearly limitless source of safe, immune-matched cells for clinical use. One of the first areas where this promise can be realized is through cell products that lack a nucleus and thus face fewer regulatory hurdles, such as red blood cells and platelets. Considerable progress has been made but scientific questions remain and improved tools to enhance the production are required if translation to clinical use is to be achieved. To this end, this FOA will support research addressing remaining scientific questions to enable and accelerate the use of stem cell-derived blood products as therapeutics. While production of sufficient numbers of cells such as platelets and red cells has been demonstrated using cellular engineering methods, basic research questions related to cell differentiation and maturation remain, which if elucidated, may allow for the development of new ways to efficiently produce clinically-useful stem cell-derived platelets or red blood cells. In addition to this FOA, two companion FOAs (RFA-HL-15-029 and RFA-HL-15-030) will support small business research to develop improved techniques and tools to enhance the production of clinically-relevant, functional stem cell-derived red blood cells or platelets in a more efficient and cost-effective manner.